Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ST266 · 1 trial · 1 indication
Determine the incidence and severity of treatment-emergent adverse events related to the IV administration of ST266 based on findings from physical examinations, laboratory evaluations, vital signs, and ECG measurements.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | 0.1 ml/kg IV ST266 once a day for 5 days |
| Cohort 2 | EXPERIMENTAL | 0.25 ml/kg IV ST266 once a day for 5 days |
| Cohort 3 | EXPERIMENTAL | 0.5 ml/kg IV ST266 once a day for 5 days |
| Cohort 4 | EXPERIMENTAL | 1.0 ml/kg IV ST266 once a day for 5 days |
| Name | Type | Description |
|---|---|---|
| ST266 | BIOLOGICAL | 1X ST266 |
Inclusion Criteria: 1. Males and non-pregnant/non-breastfeeding females age 18-70 years of age. 2. Laboratory confirmed SARS-CoV-2 infection determined by PCR or other commercial/public health assay (test results must be obtained within 7-days of the Screening Visit). 3. BMI between 18 and 39 inclu...
ST266 is an investigational monoclonal antibody being studied for the treatment of Cytokine Release Syndrome. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being evaluated for its safety and tolerability in patients with this condition.
ST266 is being developed by IQVIA Holdings, Inc., a company publicly traded under the ticker symbol IQV. The drug is currently in Phase 1 clinical development for Cytokine Release Syndrome, an immunology-related condition.
ST266 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The Phase 1 trial has been completed, and the drug remains under investigation for the treatment of Cytokine Release Syndrome.
ST266 has one completed clinical trial registered under NCT04720378, titled "Safety and Tolerability Study of IV ST266 in COVID-19 Subjects." This Phase 1 trial enrolled 12 participants in the United States and studied the drug's use in Cytokine Release Syndrome. The trial was controlled but not randomized or double-blind.
Yes, ST266 is a monoclonal antibody. It is being investigated as a potential treatment for Cytokine Release Syndrome. The drug is currently in Phase 1 clinical development and is not yet approved for any use.